Carisma Therapeutics(CARM)
$0.000.00 (0.00%)
CARM
Carisma Therapeutics financials statements
$0.00
At close:0.00 (0.00%)
Want to see CARM full AI Analyst Report?
Carisma Therapeutics (CARM) Ratios
1,711 Followers
Carisma Therapeutics Ratios
CARM's free cash flow for Q3 2025 was $1.91M. For the 2025 fiscal year, CARM's free cash flow was increased by $0.00 and operating cash flow was $1.91M. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 24 | Mar 23 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.48 | 5.06 | 2.78 | 17.77 | 3.48 |
| Quick Ratio | 1.48 | 5.06 | 2.78 | 17.77 | 3.48 |
| Cash Ratio | 1.12 | 4.88 | 1.23 | 14.06 | 3.07 |
| Solvency Ratio | -0.98 | -1.33 | -0.28 | -0.00 | -0.14 |
| Operating Cash Flow Ratio | -3.73 | -5.10 | -0.38 | -3.23 | -1.50 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -34.54M | $ 17.45M | $ -160.23M | $ 64.72M | $ -134.81M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.03 | 0.56 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.09 | 0.12 | -0.26 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -0.10 | 0.11 | -0.34 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | -0.27 | 0.00 | 0.00 |
| Financial Leverage Ratio | -1.09 | 3.38 | -0.46 | 1.82 | -20.42 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -17.87 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | -17.86 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.09 | 1.08 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.27 | 0.87 | -0.28 | 19.08 | 1.98 |
| Profitability Margins | |||||
| Gross Profit Margin | -203.96% | -396.85% | 100.00% | 99.68% | 100.00% |
| EBIT Margin | -306.54% | -594.75% | -590.61% | -32.43% | -252.56% |
| EBITDA Margin | -289.45% | -575.74% | -571.36% | -32.11% | -248.58% |
| Operating Profit Margin | -316.72% | -594.75% | -571.10% | -106.09% | -252.56% |
| Pretax Profit Margin | -308.05% | -582.34% | -622.60% | -32.43% | -252.31% |
| Net Profit Margin | -308.05% | -582.34% | -622.60% | -1.27% | -252.31% |
| Continuous Operations Profit Margin | -308.05% | -582.34% | -622.60% | -1.27% | -252.31% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 3.90% | 100.00% |
| EBT Per EBIT | 97.26% | 97.91% | 109.02% | 30.57% | 99.90% |
| Return on Assets (ROA) | -198.56% | -97.01% | -84.86% | -0.11% | -15.04% |
| Return on Equity (ROE) | 216.69% | -327.45% | 38.98% | -0.20% | 307.24% |
| Return on Capital Employed (ROCE) | -431.71% | -120.48% | -107.01% | -9.35% | -16.65% |
| Return on Invested Capital (ROIC) | -385.25% | -117.40% | -98.39% | -0.37% | -16.65% |
| Return on Tangible Assets | -198.56% | -97.01% | -84.86% | -0.12% | -21.98% |
| Earnings Yield | -348.33% | -88.45% | -12.48% | -0.23% | -17.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.85 | 0.00 | 0.00 | 1.08 | 0.00 |
| Payables Turnover | 28.68 | 18.85 | 0.00 | 0.03 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 3.06 | 1.67 | 0.73 | 617.30 | 91.35 |
| Asset Turnover | 0.64 | 0.17 | 0.14 | 0.08 | 0.06 |
| Working Capital Turnover Ratio | 0.54 | 0.30 | 0.09 | 0.22 | 0.25 |
| Cash Conversion Cycle | 40.52 | -19.37 | 0.00 | -11914.32 | 0.00 |
| Days of Sales Outstanding | 53.25 | 0.00 | 0.00 | 336.80 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 12.73 | 19.37 | 0.00 | 12251.12 | 0.00 |
| Operating Cycle | 53.25 | 0.00 | 0.00 | 336.80 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.45 | -2.42 | -0.19 | -4.09 | -4.57 |
| Free Cash Flow Per Share | -1.45 | -2.46 | -0.30 | -4.30 | -4.64 |
| Dividend Paid and CapEx Coverage Ratio | -487.13 | -6.13 | -1.62 | -19.95 | -61.39 |
| Capital Expenditure Coverage Ratio | -487.13 | -71.71 | -1.62 | -19.95 | -61.39 |
| Operating Cash Flow Coverage Ratio | -24.15 | -25.99 | -0.19 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -3.05 | -5.44 | -0.77 | -1.41 | -2.40 |
| Free Cash Flow Yield | -345.82% | -83.80% | -2.49% | -26.38% | -17.20% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.29 | -1.13 | -8.02 | -442.23 | -5.63 |
| Price-to-Sales (P/S) Ratio | 0.88 | 6.58 | 49.90 | 5.60 | 14.20 |
| Price-to-Book (P/B) Ratio | -0.62 | 3.70 | -3.12 | 0.87 | -17.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.29 | -1.19 | -40.14 | -3.79 | -5.81 |
| Price-to-Operating Cash Flow Ratio | -0.29 | -1.21 | -64.86 | -3.98 | -5.91 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.02 | -0.16 | -9.99 | 0.06 |
| Enterprise Value Multiple | -0.03 | -0.28 | -9.02 | 1.65 | -3.73 |
| Enterprise Value | 1.93M | 23.74M | 506.70M | -14.05M | 104.21M |
| EV to EBITDA | -0.03 | -0.28 | -9.02 | 1.65 | -3.73 |
| EV to Sales | 0.10 | 1.59 | 51.52 | -0.53 | 9.27 |
| EV to Free Cash Flow | -0.03 | -0.29 | -41.44 | 0.36 | -3.80 |
| EV to Operating Cash Flow | -0.03 | -0.29 | -66.97 | 0.38 | -3.86 |
| Tangible Book Value Per Share | -0.67 | 0.79 | -3.54 | 15.79 | -11.62 |
| Shareholders’ Equity Per Share | -0.67 | 0.79 | -3.90 | 18.84 | -1.56 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.96 | 0.00 |
| Revenue Per Share | 0.47 | 0.45 | 0.24 | 2.91 | 1.90 |
| Net Income Per Share | -1.46 | -2.59 | -1.52 | -0.04 | -4.80 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.04 | 1.00 |
| Interest Burden | 1.00 | 0.98 | 1.05 | 1.00 | 1.00 |
| Research & Development to Revenue | 3.04 | 4.97 | 5.76 | 0.95 | 2.07 |
| SG&A to Revenue | 1.03 | 1.98 | 0.95 | 0.00 | 0.45 |
| Stock-Based Compensation to Revenue | 0.19 | 0.16 | 0.00 | 0.02 | 0.01 |
| Income Quality | 0.99 | 0.93 | 0.12 | 0.92 | 0.95 |
Currency in USD
